Migraine affects over 44 million people in the United States alone. Migraines affect a patient’s entire life; their work, their family, and their friends. While the majority of patients can address this disease with existing therapies, fully a third of the patients who are on treatments still experience breakthrough migraines.
There are limited and sub-optimal choices for patients seeking to address these breakthrough migraines currently. Our INP104 program utilizes our POD™ technology with the gold standard in acute migraine treatment – dihydroergotamine or DHE. INP104 holds the promise of addressing breakthrough migraine with consistent and predictable delivery of DHE in an easy to use device. INP104 is currently in clinical trials to validate this promise of improved outcomes for migraine patients.